Ausgabe 3/2018
Inhalt (25 Artikel)
Efficacy and safety in older patient subsets in studies of endocrine monotherapy versus combination therapy in patients with HR+/HER2− advanced breast cancer: a review
Rachel A. Freedman, Sara M. Tolaney
Patient-reported factors associated with adherence to adjuvant endocrine therapy after breast cancer: an integrative review
Leah K. Lambert, Lynda G. Balneaves, A. Fuchsia Howard, Carolyn C. Gotay
Canine invasive mammary carcinomas as models of human breast cancer. Part 1: natural history and prognostic factors
Frédérique Nguyen, Laura Peña, Catherine Ibisch, Delphine Loussouarn, Adelina Gama, Natascha Rieder, Anton Belousov, Mario Campone, Jérôme Abadie
CD56+ immune cell infiltration and MICA are decreased in breast lobules with fibrocystic changes
Daniel Kerekes, Daniel W. Visscher, Tanya L. Hoskin, Derek C. Radisky, Rushin D. Brahmbhatt, Alvaro Pena, Marlene H. Frost, Muhammad Arshad, Melody Stallings-Mann, Stacey J. Winham, Linda Murphy, Lori Denison, Jodi M. Carter, Keith L. Knutson, Amy C. Degnim
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S. Sonke, Lowell L. Hart, Mario Campone, Frans Erdkamp, Wolfgang Janni, Sunil Verma, Cristian Villanueva, Erik Jakobsen, Emilio Alba, Erik Wist, Anne M. Favret, Thomas Bachelot, Roberto Hegg, Paul Wheatley-Price, Farida Souami, Santosh Sutradhar, Michelle Miller, Caroline Germa, Howard A. Burris
Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study
Luc Y. Dirix, Istvan Takacs, Guy Jerusalem, Petros Nikolinakos, Hendrik-Tobias Arkenau, Andres Forero-Torres, Ralph Boccia, Marc E. Lippman, Robert Somer, Martin Smakal, Leisha A. Emens, Borys Hrinczenko, William Edenfield, Jayne Gurtler, Anja von Heydebreck, Hans Juergen Grote, Kevin Chin, Erika P. Hamilton
Sensation of the autologous reconstructed breast improves quality of life: a pilot study
Anouk J. M. Cornelissen, Jop Beugels, Sander M. J. van Kuijk, Esther M. Heuts, Shai M. Rozen, Aldona J. Spiegel, René R. W. J. van der Hulst, Stefania M. H. Tuinder
The yield of targeted genotyping for the recurring mutations in BRCA1/2 in Israel
Rinat Bernstein-Molho, Yael Laitman, Hagit Schayek, Orit Reish, Shira Lotan, Sara Haim, Jamal Zidan, Eitan Friedman
The value of embedding: integrated palliative care for patients with metastatic breast cancer
M. Rabow, R. Small, A. Jow, M. Majure, A. Chien, M. Melisko, J. Belkora, L. J. Esserman, H. Rugo
Randomized placebo-controlled pilot trial of omega 3 fatty acids for prevention of aromatase inhibitor-induced musculoskeletal pain
Maryam B. Lustberg, Tonya S. Orchard, Raquel Reinbolt, Rebecca Andridge, Xueliang Pan, Martha Belury, Rachel Cole, Amanda Logan, Rachel Layman, Bhuvaneswari Ramaswamy, Robert Wesolowski, Michael Berger, Elaine Patterson, Charles Loprinzi, Charles L. Shapiro, Lisa Yee
The effect of an aerobic exercise bout 24 h prior to each doxorubicin treatment for breast cancer on markers of cardiotoxicity and treatment symptoms: a RCT
Amy A. Kirkham, Neil D. Eves, Rob E. Shave, Kelcey A. Bland, Joshua Bovard, Karen A. Gelmon, Sean A. Virani, Don C. McKenzie, Eric J. Stöhr, Darren E. R. Waburton, Kristin L. Campbell
Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer
Mothaffar F. Rimawi, Carmine De Angelis, Alejandro Contreras, Fresia Pareja, Felipe C. Geyer, Kathleen A. Burke, Sabrina Herrera, Tao Wang, Ingrid A. Mayer, Andres Forero, Rita Nanda, Matthew P. Goetz, Jenny C. Chang, Ian E. Krop, Antonio C. Wolff, Anne C. Pavlick, Suzanne A. W. Fuqua, Carolina Gutierrez, Susan G. Hilsenbeck, Marilyn M. Li, Britta Weigelt, Jorge S. Reis-Filho, C. Kent Osborne, Rachel Schiff
The effect of genetic variants on the relationship between statins and breast cancer in postmenopausal women in the Women’s Health Initiative observational study
Cathryn H. Bock, Allison M. Jay, Gregory Dyson, Jennifer L. Beebe-Dimmer, Michele L. Cote, Lifang Hou, Barbara V. Howard, Pinkal Desai, Kristen Purrington, Ross Prentice, Michael S. Simon
Clinical risk score to predict likelihood of recurrence after ductal carcinoma in situ treated with breast-conserving surgery
Rinaa S. Punglia, Wei Jiang, Stuart R. Lipsitz, Melissa E. Hughes, Stuart J. Schnitt, Michael J. Hassett, Larissa Nekhlyudov, Ninah Achacoso, Stephen Edge, Sara H. Javid, Joyce C. Niland, Richard L. Theriault, Yu-Ning Wong, Laurel A. Habel
Safety of fertility preservation in breast cancer patients in a register-based matched cohort study
Kenny A. Rodriguez-Wallberg, Sandra Eloranta, Kamilla Krawiec, Agneta Lissmats, Jonas Bergh, Annelie Liljegren
Breast cancer-related paraneoplastic neurologic disease
Brittany L. Murphy, Nicholas L. Zalewski, Amy C. Degnim, Andrew McKeon, Eoin P. Flanagan, Sean J. Pittock, Elizabeth B. Habermann
Young age at first pregnancy does protect against early onset breast cancer in BRCA1 and BRCA2 mutation carriers
DG Evans, EF Harkness, S. Howel, ER Woodward, A. Howell, F. Lalloo
Impact of microinvasion on breast cancer mortality in women with ductal carcinoma in situ
Victoria Sopik, Ping Sun, Steven A. Narod
Vitamin D supplementation decreases serum 27-hydroxycholesterol in a pilot breast cancer trial
Catherine C. Going, Ludmila Alexandrova, Kenneth Lau, Christine Y. Yeh, David Feldman, Sharon J. Pitteri
BRCA1 deficiency is a recurrent event in early-onset triple-negative breast cancer: a comprehensive analysis of germline mutations and somatic promoter methylation
Rafael Canfield Brianese, Kivvi Duarte de Mello Nakamura, Fernanda Gabriella dos Santos Ramos de Almeida, Rodrigo Fernandes Ramalho, Bruna Durães de Figueiredo Barros, Elisa Napolitano e Ferreira, Maria Nirvana da Cruz Formiga, Victor Piana de Andrade, Vladmir Claudio Cordeiro de Lima, Dirce Maria Carraro
Duration of trastuzumab in HER2-positive metastatic breast cancer after complete remission: still debatable issue?
Kadri Altundag
Hormone receptor-positive invasive lobular and ductal carcinoma of the breast have comparable hormone receptor expression levels both if detected by screening and clinically
Alessandra Ravaioli, Fabio Falcini, Lauro Bucchi
Does the elevation of CAMLs predict metastatic breast cancer patients’ survival?
Qixing Tan, Qinghong Qin
Dose adjustment in obese breast cancer patients receiving neoadjuvant chemotherapy might have an impact on survival
Kadri Altundag